Factor Bioscience

Executive Summary

Factor Bioscience is a pre-clinical biotechnology company based in Cambridge, Massachusetts, focused on advancing cell engineering through innovations in mRNA, gene editing, cell reprogramming, and nucleic acid delivery. Founded in 2011, the company aims to unlock the potential of cell therapies to treat a broad range of diseases. As a private entity with no disclosed funding or valuation, Factor Bioscience operates in the competitive gene and cell therapy space, leveraging its proprietary platform to develop next-generation cell therapies. Despite its early stage, the company's focus on mRNA-based approaches aligns with industry trends toward non-viral delivery methods. However, the lack of public data on pipeline progress and regulatory milestones introduces significant execution risk. The coming years will be critical for demonstrating preclinical proof-of-concept and securing capital to advance toward clinical trials.

Upcoming Catalysts (preview)

• H2 2026Advancement of lead program to IND-enabling studies30% success
• 2026Series A or B financing round50% success
• 2026Strategic partnership or licensing deal for platform technology20% success